Literature DB >> 33452674

15-Deoxy-Δ12,14 -prostaglandin J2 binds and inactivates STAT3 via covalent modification of cysteine 259 in H-Ras-transformed human breast epithelial cells.

Su-Jung Kim1, Nam-Chul Cho2, Bitnara Han3, Kyeojin Kim1, Young-Il Hahn4, Kwang Pyo Kim3,5, Young Ger Suh6, Bu Young Choi7, Hye-Kyung Na8, Young-Joon Surh1,4,9.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) has been considered as a potential target for development of anticancer therapeutics. Here, we report a novel mechanism by which the cyclopentenone prostaglandin, 15-deoxy-Δ12,14 -prostaglandin J2 (15d-PGJ2 ) functions as an allosteric inhibitor of STAT3. 15d-PGJ2 inhibits phosphorylation, dimerization, nuclear translocation, and transcriptional activity of STAT3 in H-Ras-transformed human mammary epithelial cells (MCF10A-Ras) through the Michael addition reaction at cysteine 259 of STAT3. Comparative studies with 15d-PGJ2 analogues reveal that both C12-C13 and C9-C10 double bonds conjugated to the carbonyl group in the cyclopentenone ring of 15d-PGJ2 are essential for STAT3 binding. Antiproliferative and pro-apoptotic activities of 15d-PGJ2 in MCF10A-Ras cells are attributable to covalent modification of STAT3 on Cys259, and mimic the effects induced by mutation of this amino acid.
© 2021 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Entities:  

Keywords:  15-deoxy-∆12,14-prostaglandin J2; STAT3; breast cancer; cyclopentenone prostaglandin; thiol modification; α,β-unsaturated carbonyl group

Year:  2021        PMID: 33452674     DOI: 10.1002/1873-3468.14040

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  1 in total

1.  15-Deoxy-△12,14-Prostaglandin J2 Promotes Resolution of Experimentally Induced Colitis.

Authors:  Wonki Kim; Jeong-Hoon Jang; Xiancai Zhong; Hyungseok Seo; Young-Joon Surh
Journal:  Front Immunol       Date:  2021-02-02       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.